Lipocine Inc. (LPCN)
| Market Cap | 60.58M |
| Revenue (ttm) | 16.64M |
| Net Income (ttm) | 3.42M |
| Shares Out | 88.51M |
| EPS (ttm) | 0.04 |
| PE Ratio | 17.11 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 236,694 |
| Open | 0.710 |
| Previous Close | 0.704 |
| Day's Range | 0.684 - 0.728 |
| 52-Week Range | 0.670 - 1.890 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 3.70 (+440.6%) |
| Earnings Date | Aug 8, 2022 |
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for LPCN stock is "Buy." The 12-month stock price forecast is 3.7, which is an increase of 440.62% from the latest price.
News
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022
SALT LAKE CITY , Aug. 8, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") di...
FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment
Phase 2 Photosensitive Epilepsy Study Planned for 2H 2022 SALT LAKE CITY, July 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative product...
LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS
SALT LAKE CITY , June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Patent ...
LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE
SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, presented "L...
Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with extended LPCN 1144 treatment Observed liver histology improvement...
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
SALT LAKE CITY , May 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, today announc...
LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS
Industry veterans Jill M. Jene, Ph.D.
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™
Commercial launch expected in 2Q 2022 SALT LAKE CITY , March 29, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products f...
Lipocine Announces Financial Results for the Year Ended December 31, 2021
SALT LAKE CITY, March 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced financial result...
Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH
SALT LAKE CITY, March 1, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today provided an update from th...
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®
SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic and endocrine disorders, tod...
Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®
SALT LAKE CITY , Jan. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer-reviewed pu...
Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference
SALT LAKE CITY, Jan. 5, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that one abstract has ...
LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSIS
SALT LAKE CITY, Dec. 22, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patien...
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021
SALT LAKE CITY, Nov. 10, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for...
Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH
SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Ad...
Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) ...
SALT LAKE CITY, Nov. 1, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that three abstracts h...
Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US
Lipocine Inc (NASDAQ: LPCN) has entered into an exclusive licensing agreement with Antares Pharma Inc (NASDAQ: ATRS) to commercialize Tlando in the U.S. Tlando is an oral testosterone product for testo...
Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®
SALT LAKE CITY, Oct. 18, 2021 /PRNewswire/ -- Under the terms of Agreement Lipocine to receive: Up to $21.0 million in licensing fees, including $11.0 million payable immediately and $10.0 million to be...
Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference
SALT LAKE CITY, Oct. 5, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will ...
Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®
SALT LAKE CITY, Sept. 28, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the U.S. Food and Dr...
Lipocine to Present at The Cantor Fitzgerald Virtual Global Healthcare Conference
SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company wil...
Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment Conference
SALT LAKE CITY , Sept. 1, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company wil...
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
Lipocine Inc (NASDAQ: LPCN) has announced topline 36-week results from its Phase 2 proof of concept LiFT study investigating LPCN 1144 in Non-Alcoholic Steatohepatitis (NASH). LPCN 1144 comprises an ora...